Alectinib (ALECENSA) is THE ONLY preferred first-line treatment option (Category 1) for ALK+ metastatic NSCLC in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) 4*†
*When an ALK rearrangement is discovered
prior to first-line systemic therapy.
†The NCCN Guidelines for NSCLC provide recommendations for individual biomarkers that should be tested and recommend testing techniques, but do not endorse any specific commercially available biomarker assays.
CNS Efficacy in 1L ALK+ mNSCLC
Learn more about CNS efficacy with ALECENSA.
Dosing and Administration
Learn about dosing and monitoring for ALECENSA.
Financial Support for Patients
Learn more about ALECENSA patient and practice resources.